Insmed Taps Pharma Veteran Samuele Butera for Respiratory Leadership
Insmed Incorporated has appointed Samuele Butera as Senior Vice President and General Manager of its Global Respiratory division. Butera, who previously led pulmonary hypertension and vaccine initiatives at Johnson & Johnson, joins the executive committee to oversee the commercial rollout of BRINSUPRI and the expansion of the ARIKAYCE portfolio.
Butera arrives at the Bridgewater-based biopharmaceutical firm with over two decades of commercial experience across global markets. His mandate includes steering the company’s respiratory therapeutic area, a core pillar of Insmed’s clinical and commercial strategy. He will report directly to Chair and CEO Will Lewis, who highlighted Butera’s track record in navigating competitive therapeutic landscapes as a primary driver for the hire.
Before his tenure at Johnson & Johnson, where he managed a multi-billion-dollar business unit, Butera held senior roles at Novartis. His background includes overseeing the global launch of the CAR-T therapy KYMRIAH and holding leadership positions at Sandoz Biopharmaceuticals. His earlier career includes stints at McKinsey & Company and Goldman Sachs, alongside work with the United Nations. Butera holds a Master in Public Policy from Harvard and a degree in International Economics from Università Bocconi.
Comments (0)
No comments yet. Be the first!